Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University of Munich, Munich, Germany.
Department of Chemical Biology, Helmholtz Centre for Infection Research, Braunschweig, Germany.
J Neuromuscul Dis. 2022;9(5):607-614. doi: 10.3233/JND-220810.
Anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR)-myopathy is a usually rapidly progressive form of immune-mediated necrotizing myopathy (IMNM). Rarer clinical courses show slow progression and resemble the phenotype of limb-girdle dystrophy (LGMD).
We demonstrate the difficulties in differentiating LGMD versus anti-HMGCR-myopathy.
We report on a 48-year-old patient with slowly progressive tetraparesis and hyperCKemia for more than 20 years.
Due to myopathic changes in initial and second muscle biopsy and typical clinical presentation, the patient was diagnosed with LGMD 20 years ago; despite comprehensive genetic testing including exome diagnostics, the genetic cause of disease could not be identified. Finally, HMG-CoA reductase antibodies were detected, confirming the diagnosis of anti-HMGCR-myopathy. By re-work-up of a second muscle biopsy specimen from year 2009, the diagnosis of a IMNM was made in retrospect. Seven cycles of high-dose immunoglobulins were administered; patient reported outcome measures have mildly improved.
Patients with clinical LGMD phenotype, degenerative changes in muscle biopsy but without genetic confirmation of the disease should be tested for HMG-CoA-myopathy, thereby allowing for an early start of treatment.
抗 3-羟基-3-甲基戊二酰辅酶 A 还原酶(HMGCR)-肌病是一种通常进展迅速的免疫介导性坏死性肌病(IMNM)。更罕见的临床病程表现为缓慢进展,类似于肢带型肌营养不良症(LGMD)的表型。
我们展示了区分 LGMD 与抗 HMGCR 肌病的困难。
我们报告了一名 48 岁的患者,其表现为进行性四肢无力和高肌酸激酶血症超过 20 年。
由于初始和第二次肌肉活检存在肌病改变以及典型的临床表现,该患者 20 年前被诊断为 LGMD;尽管进行了包括外显子组诊断在内的全面基因检测,但仍无法确定疾病的遗传原因。最终,检测到 HMG-CoA 还原酶抗体,从而确诊为抗 HMGCR 肌病。通过重新检查 2009 年的第二次肌肉活检标本,回顾性诊断为 IMNM。给予了 7 个周期的高剂量免疫球蛋白治疗;患者的报告结果测量指标有轻度改善。
对于具有临床 LGMD 表型、肌肉活检存在退行性改变但未遗传确诊的患者,应进行 HMG-CoA 肌病检测,从而能够早期开始治疗。